Company intelligence / Profile preview
Georgiamune
Gaithersburg, Maryland, United Statesgeorgiamune.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Georgiamune has advanced two first-in-class clinical assets into human trials within five months of each other. GIM‑122, a dual-functioning monoclonal antibody designed to overcome immunotherapy resistance in cancer patients, received IND clearance in August 2023. GIM‑531, an oral small molecule that selectively inhibits T-regulatory cells to restore anti-tumor immunity, received IND clearance in May 2024. Both are being tested for safety and efficacy in advanced solid tumors. The company claims three drugs are already undergoing clinical trials with more under development.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Small molecules (oral therapies)Immunomodulators
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Parker Institute for Cancer Immunotherapy among investors; no explicit pharma partnerships disclosed but strong academic roots noted.
Beyond the preview
Go deeper on Georgiamune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Georgiamune.